Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 721

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 721
---
31, 2023 |
|:---------------------------------------------------------------------------------------------------------------|:--|:--|-------------------:|:--|:--|------------------:|
| Cash and cash equivalents                                                                                      | ​ | $ |             37,061 | ​ | $ |            51,775 |
| Restricted cash, current assets                                                                                | ​ |   |              1,500 | ​ |   |               408 |
| Restricted cash, long-term assets                                                                              | ​ |   |                  — | ​ |   |             1,500 |
| Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows | ​ | $ |             38,561 | ​ | $ |            53,683 |

7.Inventory, net

Inventory, net consists of the following:

| ​                                       | ​ 
 ​ | ​ |                  ​ 
 September 30, 2024 | ​ | ​ |                 ​ 
 December 31, 2023 |
|:----------------------------------------|:--|:--|-------------------:|:--|:--|------------------:|
| Raw materials                           | ​ | $ |              2,124 | ​ | $ |             2,639 |
| Work-in-process                         | ​ |   |                 16 | ​ |   |               708 |
| ​                                       | ​ | ​ |              2,140 | ​ | ​ |             3,347 |
| Less Inventory Reserve for Obsolescence | ​ |   |             -1,515 | ​ |   |              -526 |
| Total                                   | ​ | $ |                625 | ​ | $ |             2,821 |

As of September 30, 2024 and December 31, 2023, inventory balances include inventory costs subsequent to regulatory approval of KORSUVA injection on August 23, 2021. During the three and nine months ended September 30, 2024, the Company wrote down$ 1,020and$ 2,509, respectively, of commercial supply inventory due to obsolescence.

F- 15

CARA THERAPEUTICS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (amounts in thousands, except share and per share data) (unaudited)

8. Prepaid expenses As of September 30, 2024, prepaid expenses were $ 2,382 , consisting of $ 1,650 of prepaid R&D